#VisualAbstract: Atezolizumab With Carboplatin in Patients With Metastatic Triple-Negative Breast Cancer | 2 Minute Medicine
2 Minute Medicine ,
1. Progression-free survival was 4.1 months in the combination arm vs 2.2 months in the monotherapy arm with an HR of 0.66.